Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells.

AUTOR(ES)

Traunecker, A

RESUMO

The human immunodeficiency virus type 1 (HIV-1) uses cell surface CD4 as a receptor to infect susceptible cells. Therefore, different forms of soluble CD4 (sCD4) molecules have been developed recently for potential therapeutic purposes. Here we describe a novel design of sCD4 molecules which exploit cytotoxic T cells as their effector function. The principle of bispecific antibodies was exploited and further developed to create new bispecific reagents which could retarget cytotoxic T cells of any specificity and thus, induce killing of HIV-1 infected cells. The most advanced molecules, Janusins, contain in one polypeptide chain the first two N-terminal CD4 domains and single chain combining site against the human CD3 complex (FvCD3).

Documentos Relacionados

• Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells.
• Rotavirus-specific cytotoxic T lymphocytes cross-react with target cells infected with different rotavirus serotypes.
• HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals.
• Enhanced susceptibility to cytotoxic T lymphocytes of target cells isolated from virus-infected or interferon-treated mice.
• Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes.